UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 18, 2015
XBIOTECH INC.
(Exact name of registrant as specified in its charter)
British Columbia, Canada
(State of Incorporation)
001-37347
(Commission File Number)
N/A
(IRS Employer Identification No.)
| 8201 E Riverside Dr. Bldg 4, Ste 100 Austin, Texas | 78744 |
| (Address of principal executive offices) | (Zip Code) |
(512) 386-2930
(Registrant's telephone number, including area code)
________________________________________________________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events.
On May 18, 2015, XBiotech Inc. (the "Company") , announced that it has secured approval from the Data Safety Monitoring Board ("DSMB") to continue its Phase 3 registration study in Europe for Xilonix™, its novel cancer immunotherapy. The DSMB also recommended a sample size increase in the study, which was within the Company's expectations. Enrollment remains on pace to meet the completion timelines. A copy of the Company's press release announcing the foregoing is attached as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) | Exhibits. |
99.1 | Press Release of XBiotech Inc., issued May 18, 2015 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| XBIOTECH INC. (Registrant) | ||
| May 18, 2015 (Date) | /s/ JOHN SIMARD John Simard Chief Executive Officer and President |
EXHIBIT INDEX
Exhibit |
| |
99.1 | Press Release, issued May 18, 2015 |
